Nasdaq GlobeNewswire

GRID2020 and SMUD Tag Team Power Theft

Del

RICHMOND, Va., 2016-08-16 17:54 CEST (GLOBE NEWSWIRE) -- GRID2020, Inc., a leading distribution transformer monitoring solutions provider released a statement today regarding its ongoing collaborations with Sacramento Municipal Utility District (SMUD).

Alan Snook, President GRID20/20 stated, “As we continue to introduce our OptaNODETM intra-grid sensor solution into domestic and international markets, it is incredibly rewarding to see our utility customers achieving substantial success.   We have recently announced various utility success stories to the marketplace, and SMUD’s latest achievement is yet another that deserves recognition.”

Throughout the last year, the Revenue Assurance team at SMUD has been leveraging GRID20/20’s OptaNODETM DTM and PDTM sensors to identify power theft within its grid space.   While the efforts have been very surgical in nature, the results have been exceptional.

Dan Miller, Supervisor Revenue Assurance at SMUD commented, “We strategically deployed a series of OptaNODETM devices into our grid beginning in 2015.  Since then, we have identified and shut down $376,652.42 of power theft.” 

Power Theft, which is touted by some to exceed $6 billion per year in the U.S. alone, is a perpetual concern for utilities.   Not only are there significant costs associated with the stolen power, but a series of related operations impacts that subsequently burden electricity providers.   In essence, distribution transformers are initially sized by utility operators to service the anticipated loading for the respective location.   However, when power theft occurs, excessive unplanned loading then negatively impacts the associated transformers.   This type of unauthorized power demand commonly overloads transformers beyond their rated performance levels.  Often this can result in premature aging of transformers, and eventual power outages. 

With the introduction of intra-grid sensors such as the GRID20/20 suite of devices, utilities can now effectively locate instances of power theft, and help to avoid the excessive costs that ultimately effect rate payers.  Using the GRID20/20 solution, utilities can now cost-effectively embrace a proactive posture and prevent unnecessary cost burdens from landing upon their valued customer’s monthly billing statements.

GRID20/20 provides a growing list of value propositions for electricity providers by effectively leveraging transformers within the distribution grid.   The accurate, timely data captured from within the heart of the grid enables utility operators to directly and immediately create operations efficiencies, reduce power outages, and decrease unnecessary losses.

For more information about GRID20/20, visit www.grid2020.com.

         K.B. Forbes,
         kb@kbforbes.com
         +1(202)320-1212

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

ERYTECH Pharma Reports Voting Results from Annual General Meeting Held on June 28, 201817.7.2018 22:30Pressemelding

LYON, France and CAMBRIDGE, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- ERYTECH Pharma (Euronext:ERYP) (Nasdaq:ERYP) announced that its 2018 Annual General Meeting was held in Lyon on Thursday, June 28, 2018. At the meeting, all resolutions for which management recommended a vote in favor, were adopted, including: - Approval of the annual financial statements and consolidated financial statements for the year ended December 31, 2017 and quietus of directors; - Allocation of the financial year's results; - Approval of regulatory agreements and commitments referred to in Article L.225-38 of the French Commercial Code; - Approval of the regulations of the share subscription and/or purchase options plan adopted by the Board of Directors on June 27, 2017; - Authorization for the Board of Directors to grant share subscription and/or share purchase options and/or to issue detachable share subscription warrants to corporate officers and employees of the Company or companies in the ERYTECH Pharma

Williams Scotsman Receives Competition Bureau Clearance for ModSpace Acquisition17.7.2018 22:15Pressemelding

BALTIMORE, July 17, 2018 (GLOBE NEWSWIRE) -- WillScot Corporation (NASDAQ:WSC) ("Williams Scotsman"), a specialty rental services market leader providing innovative modular space and portable storage solutions across North America, today announced that, on July 16, 2018, the Canadian Competition Bureau issued a No Action Letter relating to Williams Scotsman's proposed acquisition of Modular Space Corporation ("ModSpace"). WillScot has now obtained the regulatory approvals required to complete the acquisition and continues to progress towards closing in the third quarter of 2018. About Williams Scotsman Headquartered in Baltimore, Maryland, WillScot Corporation is the public holding company for the Williams Scotsman family of companies in the United States, Canada and Mexico. WillScot Corporation trades on the NASDAQ stock exchange under the ticker symbol "WSC." Williams Scotsman is a specialty rental services market leader providing innovative modular space and portable storage solutio

Minerva Neurosciences Elects Jeryl Hilleman to Board of Directors17.7.2018 22:05Pressemelding

WALTHAM, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of Jeryl Hilleman to the Board of Directors of the Company. "Jeri brings a broad life sciences background to Minerva that includes high growth commercial biopharma, med-tech and data science companies," said William F. Doyle, Lead Independent Director of Minerva. "Her track record of delivering strategic and financial growth through execution, strategic partnering and multiple acquisitions will serve Minerva well as the Company completes five ongoing late-stage clinical trials with roluperidone, seltorexant and MIN-117." Ms. Hilleman is presently Chief Financial Officer of Intersect ENT (NASDAQ:XENT), a medical device company with commercial products for the treatment of chronic sinusitis. Previously, she served as CFO of several public

Orion Biotechnology Awarded a $2M Grant from National Center for Research and Development to Fund Further Development of its HIV Microbicide17.7.2018 21:00Pressemelding

OTTAWA, July 17, 2018 (GLOBE NEWSWIRE) -- Orion Biotechnology Canada Ltd., a developer of novel medical treatments, today announced that its European subsidiary, Orion Biotechnology Polska Sp. z o.o., was awarded a grant of $2M US dollars by the National Center for Research and Development . The grant will fund a project to advance development of the company's innovative microbicide candidate (OB-002H). Designed to prevent the transmission of HIV, OB-002H has the potential to address an urgent and growing need for an HIV prevention product that is affordable, appealing to use, and easily integrates into the lifestyles of people at risk for HIV infection regardless of age, sex or gender. The project is co-financed by the National Center for Research and Development under the InnoNeuroPharm program - Measure 1.2: Sectoral R & D programs of the Intelligent Development Operational Program 2014-2020. Orion Biotechnology will use the grant to complete IND enabling studies, advance OB-002H to

Greater Anglia Selects PowerPlan to Optimise Its Asset Investments17.7.2018 15:29Pressemelding

ATLANTA, July 17, 2018 (GLOBE NEWSWIRE) -- Greater Anglia, a UK-based train operating company, has selected PowerPlan's Asset Investment Optimization software suite to maximise its asset investments over a 40-year time period. Greater Anglia's long-term investment strategy includes a 40-year asset plan to meet its regulatory requirements. For what was historically built with manual processes and not easily tracked, the Asset Investment Optimization solution from PowerPlan will provide a comprehensive, auditable approach to help the company analyze different investment scenarios for impacts to risk, cost, timing and level of service and provide a defendable asset plan for the next four decades. "The condition of our assets drives our business," said Richard Turner, Head of Asset Management for Greater Anglia. "With PowerPlan, we can apply a fact-based methodology to prioritise investments, maximise their return and produce plans that communicate our asset strategy to internal and extern

Oxford Immunotec Schedules Second Quarter 2018 Earnings Release and Conference Call for July 31, 201817.7.2018 14:30Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., July 17, 2018 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company, today announced that it plans to release second quarter 2018 financial results prior to market open on Tuesday, July 31, 2018. Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers or +1 (484) 365-2897 for international callers and reference confirmation code 9268558, approximately ten minutes prior to start time. To access the live audio webcast or subsequent archived recording, visit the Investor Relations section of Oxford Immunotec's website at www.oxfordimmunotec.com. The replay will be available on the Company's website for approximately

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom